.jpg?format=webp&quality=80&width=3840)
A review of prospective studies on ablative therapies for prostate cancer reveals that 65% of patients had grade group ≥2 cancer initially. One year post-treatment, 25.7% experienced in-field treatment failure with ≥GG1 and 8.8% with ≥GG2. Residual cancer was found in 43.7% and 13.0% of men for ≥GG1 and ≥GG2, respectively, during post-treatment biopsies. While erectile function decreased by 8.8%, 78.7% maintained potency after targeted focal therapy. Long-term data is limited, but 13% experienced oncologic failure at 6-12 months. The study provides valuable insights for future trials and technique benchmarking.
Like
Save
Share